Injectable GLP-1s such as Wegovy have also demonstrated cardiovascular risk reduction in high-risk patients, an advantage not yet confirmed for the upcoming oral versions
Therefore, the aforementioned novel applications of GLP-1RAs all have the potential to bolster treatment and management options for the field as a whole, and new research continues to illuminate the physiological mechanisms behind this observed neuroprotective effect
That's not microdosing
The study indicates that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of the lean mass loss typically associated with GLP-1 therapy, while increasing fat loss
There was a progressive decrease of the proportion of patients at target for each 0.5% increase in baseline HbA1c, ranging from 57.8% for HbA1c 7.5% to 20.8% for HbA1c 10% (p for trend 9.0% with no further decrease, whereas for non-insulin drugs the relationship was continuous without any evidence of plateau 5
Its not hard to understand why sticking with this regime is challenging a large minority of patients report unpleasant side effects such as nausea and vomiting, and some experience additional side effects such as injection-site reactions, infections, heart burn, and headaches
